Arcus Biosciences Inc’s filing revealed that its Chief Operating Officer Jarrett Jennifer unloaded Company’s shares for reported $0.2 million on Mar 27 ’24. In the deal valued at $17.55 per share,11,551 shares were sold. As a result of this transaction, Jarrett Jennifer now holds 215,253 shares worth roughly $3.76 million.
Then, Jarrett Jennifer sold 13,449 shares, generating $240,941 in total proceeds. Upon selling the shares at $17.92, the Chief Operating Officer now owns 226,804 shares.
Before that, Jarrett Jennifer sold 34,070 shares. Arcus Biosciences Inc shares valued at $685,148 were divested by the Chief Operating Officer at a price of $20.11 per share. As a result of the transaction, Jarrett Jennifer now holds 240,253 shares, worth roughly $4.19 million.
BofA Securities initiated its Arcus Biosciences Inc [RCUS] rating to a Neutral in a research note published on November 18, 2022; the price target was $33. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who began to cover the stock in mid October with a ‘”an Overweight”‘ rating. Berenberg started covering the stock on November 24, 2020. It rated RCUS as “a Buy”.
Price Performance Review of RCUS
On Tuesday, Arcus Biosciences Inc [NYSE:RCUS] saw its stock jump 2.83% to $17.45. Over the last five days, the stock has lost -1.52%. Arcus Biosciences Inc shares have fallen nearly -8.64% since the year began. Nevertheless, the stocks have fallen -0.68% over the past one year. While a 52-week high of $25.47 was reached on 02/27/24, a 52-week low of $12.95 was recorded on 02/02/24. SMA at 50 days reached $17.39, while 200 days put it at $17.84. A total of 0.5 million shares were traded, compared to the trading of 0.58 million shares in the previous session.
Levels Of Support And Resistance For RCUS Stock
The 24-hour chart illustrates a support level at 16.97, which if violated will result in even more drops to 16.50. On the upside, there is a resistance level at 17.78. A further resistance level may holdings at 18.12. The Relative Strength Index (RSI) on the 14-day chart is 48.38, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.20, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 55.15%. Stochastics %K at 38.32% indicates the stock is a holding.
How much short interest is there in Arcus Biosciences Inc?
A steep rise in short interest was recorded in Arcus Biosciences Inc stocks on Mar 15, 2024, growing by 0.46 million shares to a total of 7.98 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 7.52 million shares. There was a rise of 5.76%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 13.18% of the overall stock float, the days-to-cover ratio (short ratio) rose to 7.57.
The most recent change occurred on November 23, 2020 when Evercore ISI began covering the stock and recommended ‘”an Outperform”‘ rating .
